Compounds > miramistin
Page last updated: 2024-12-06

miramistin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

miramistin: do not confuse with alkamides [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72949
CHEMBL ID4650346
SCHEMBL ID2236560
MeSH IDM0162089

Synonyms (37)

Synonym
miramistin
myramistin
miramystin
126338-77-0
15809-19-5
benzyldimethyl(3-tetradecamidopropyl)ammonium chloride
ammonium, benzyldimethyl(3-myristamidopropyl)-, chloride
dt 2 (surfactant)
benzyldimethyl(3-((1-oxotetradecyl)amino)propyl)ammonium chloride
unii-ql5j8f55lh
einecs 239-908-9
benzenemethanaminium, n,n-dimethyl-n-(3-((1-oxotetradecyl)amino)propyl)-, chloride
ql5j8f55lh ,
SCHEMBL2236560
miramistin [who-dd]
benzenemethanaminium, n,n-dimethyl-n-(3-((1-oxotetradecyl)amino)propyl)-, chloride (1:1)
benzyldimethyl(3-myristoylamino)propyl) ammonium chloride
miramistin [mart.]
dt 2
AKOS030524146
D71059
benzyldimethyl[3-[(1-oxotetradecyl)amino]propyl]ammonium chloride
myristamidopropyldimethylbenzylammonium chloride
c26h47cln2o
DTXSID20925509
Q4295526
DS-19584
n-benzyl-n,n-dimethyl-3-tetradecanamidopropan-1-aminium chloride
benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride
n-benzyl-n,n-dimethyl-3-tetradecanamidopropan-1-aminiumchloride
myramistin;miramistin
BCP26374
CHEMBL4650346
CS-0029304
benzyldimethyl(3-tetradecanamidopropyl)azanium chloride
EN300-26515790
Z3247509968

Research Excerpts

Overview

Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms and a clinical profile showing good tolerability. It was developed in the Soviet Union during the Cold War.

ExcerptReferenceRelevance
"Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms and a clinical profile showing good tolerability. "( The antiseptic Miramistin: a review of its comparative in vitro and clinical activity.
Denning, DW; Farooq, Z; Osmanov, A; Richardson, MD, 2020)		2.35
"Miramistin is a topical antiseptic with broad antimicrobial activity that was developed in the Soviet Union during the Cold War."( In vitro and in vivo efficacy of miramistin against drug-resistant fungi.
Denning, DW; Osmanov, A; Wise, A, 2019)		2.24

Treatment

ExcerptReferenceRelevance
"Treatment with Miramistin inhibited biofilm formation by 2-3 times compared to the control."( Effects of Miramistin and Phosprenil on Microbial Biofilms.
Adzhieva, AA; Danilina, GA; Danilova, TA; Minko, AG; Nikolaeva, TN; Pronin, AV; Zhukhovitskii, VG, 2017)		1.18

Compound-Compound Interactions

ExcerptReferenceRelevance
"Experience of clinical treatment of 9 patients with diabetes mellitus and diabetic angiopathy using alprostan in combination with rays "Bioptron-II" and iruxol-miramistinum in conditions of polyclinic was summarized."( [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis].
Tomashuk, II; Tomashuk, IP, 2001)		0.73

Dosage Studied

ExcerptRelevanceReference
"1 mg dosage in 150-200 ml isotonic solution of sodium chloride during 15 days."( [Clinical efficacy of alprostan in combination with "Bioptron-II" rays and iruxol-miramistin in the treatment of the diabetic foot complicated by atherosclerosis].
Tomashuk, II; Tomashuk, IP, 2001)		0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1684364Antibacterial activity against methicillin- resistant Staphylococcus intermedius 1143 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761373Antibacterial activity against clinical isolate Serratia marcescens 1966 measured after 24 hrs by broth microdilution method
AID1684355Antibacterial activity against methicillin- resistant Pseudomonas spp. clinical isolate 6 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684398Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684369Selectivity index, ratio of CC50 for human HSF cells to MIC for Klebsiella pneumoniae ATCC 18132021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761358Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus intermedius 1061 measured after 24 hrs by broth microdilution method
AID1761356Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 983 measured after 24 hrs by broth microdilution method
AID1761364Antibacterial activity against clinical isolate Enterococcus faecalis 3063 measured after 24 hrs by broth microdilution method
AID1684362Antibacterial activity against methicillin- resistant Staphylococcus aureus 25 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684374Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761379Antibacterial activity against Escherichia coli assessed as fold increase in MIC after 4 passages by serial dilution method
AID1761340Antibacterial activity against Escherichia coli MG 1655 measured after 24 hrs by broth microdilution method
AID1761343Cytotoxicity against human mesenchymal stem cells assessed as cell viability measured after 72 hrs by MTT assay
AID1761362Antibacterial activity against clinical isolate Staphylococcus aureus 25 measured after 24 hrs by broth microdilution method
AID1684379Bactericidal activity against Staphylococcus epidermidis assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684372Selectivity index, ratio of CC50 for human HSF cells to MIC for Staphylococcus epidermidis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684391Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684366Antibacterial activity against methicillin- resistant Staphylococcus aureus 967 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761337Antibacterial activity against Staphylococcus aureus ATCC 29213 measured after 24 hrs by broth microdilution method
AID1761371Antibacterial activity against clinical isolate Klebsiella pneumoniae 1813 measured after 24 hrs by broth microdilution method
AID1684394Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684352Antibacterial activity against methicillin- resistant Proteus sp. clinical isolate 17 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684354Antibacterial activity against methicillin- resistant Klebsiella sp. clinical isolate 11 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761372Antibacterial activity against clinical isolate Pseudomonas aeruginosa 1945 measured after 24 hrs by broth microdilution method
AID1761385Acute toxicity in po dosed C57BL/6CBA mouse measured upto 7 days
AID1684357Antibacterial activity against methicillin- resistant Acinetobacter spp. clinical isolate 3 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684353Antibacterial activity against methicillin- resistant Klebsiella sp. clinical isolate 12 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761342Cytotoxicity against human HEK293 cells assessed as cell viability measured after 72 hrs by MTT assay
AID1761363Antibacterial activity against clinical isolate Enterococcus faecalis 23 measured after 24 hrs by broth microdilution method
AID1761366Antibacterial activity against clinical isolate Pseudomonas sp. 5 measured after 24 hrs by broth microdilution method
AID1761369Antibacterial activity against clinical isolate Escherichia coli 718 measured after 24 hrs by broth microdilution method
AID1761355Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 713 measured after 24 hrs by broth microdilution method
AID1761359Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 1065 measured after 24 hrs by broth microdilution method
AID1761341Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after 24 hrs by broth microdilution method
AID1684395Antibacterial activity against Staphylococcus epidermidis assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684376Bactericidal activity against Klebsiella pneumoniae ATCC 1813 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684363Antibacterial activity against methicillin- resistant Staphylococcus aureus 2020 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684397Antibacterial activity against Klebsiella pneumoniae ATCC 1813 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684375Bactericidal activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761344Cytotoxicity against human skin fibroblasts assessed as cell viability measured after 72 hrs by MTT assay
AID1684358Antibacterial activity against methicillin- resistant Acinetobacter spp. clinical isolate 1 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684359Antibacterial activity against methicillin- resistant Moraxella sp.829 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761368Antibacterial activity against clinical isolate Proteus sp. 17 measured after 24 hrs by broth microdilution method
AID1761339Antibacterial activity against Micrococcus luteus clinical isolate measured after 24 hrs by broth microdilution method
AID1684365Antibacterial activity against methicillin- resistant Staphylococcus aureus 983 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684360Antibacterial activity against methicillin- resistant Moraxella sp.765 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761357Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 1053 measured after 24 hrs by broth microdilution method
AID1761361Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus intermedius 1143 measured after 24 hrs by broth microdilution method
AID1761360Antibacterial activity against clinical isolate methicillin-resistant Staphylococcus aureus 1131 measured after 24 hrs by broth microdilution method
AID1684377Bactericidal activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761336Antibacterial activity against clinical isolate Staphylococcus ureilyticus 1972 measured after 24 hrs by broth microdilution method
AID1761393Lipophilicity, logP of the compound
AID1684380Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684370Selectivity index, ratio of CC50 for human HSF cells to MIC for Escherichia coli ATCC 259222021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684373Selectivity index, ratio of CC50 for human HSF cells to MIC for Staphylococcus aureus ATCC 292132021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761378Antibacterial activity against Staphylococcus aureus assessed as fold increase in MIC after 8 passages by serial dilution method
AID1684378Bactericidal activity against Bacillus subtilis 168 assessed as reduction in bacterial growth incubated for 24 hrs followed by replating on MH broth and further incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684356Antibacterial activity against methicillin- resistant Acinetobacter spp. clinical isolate 5 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684396Antibacterial activity against Bacillus subtilis 168 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684368Selectivity index, ratio of CC50 for human HSF cells to MIC for Pseudomonas aeruginosa ATCC 278532021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761365Antibacterial activity against clinical isolate Acinetobacter sp. 3 measured after 24 hrs by broth microdilution method
AID1684367Antibacterial activity against methicillin- resistant Staphylococcus haemolyticus 837 assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1684371Selectivity index, ratio of CC50 for human HSF cells to MIC for Bacillus subtilis 1682021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
AID1761370Antibacterial activity against clinical isolate Moraxella 765 measured after 24 hrs by broth microdilution method
AID1761367Antibacterial activity against clinical isolate Klebsiella sp. 11 measured after 24 hrs by broth microdilution method
AID1761338Antibacterial activity against Bacillus subtilis 168 measured after 24 hrs by broth microdilution method
AID1684361Antibacterial activity against methicillin- resistant Moraxella sp.764 clinical isolate assessed as reduction in bacterial growth incubated for 24 hrs by CLSI broth microdilution method2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Thiacalixarene based quaternary ammonium salts as promising antibacterial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.23)18.7374
1990's8 (25.81)18.2507
2000's8 (25.81)29.6817
2010's8 (25.81)24.3611
2020's6 (19.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.04 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index101.79 (26.88)
Search Engine Supply Index3.02 (0.95)

This Compound (46.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.50%)5.53%
Reviews2 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.50%)0.25%
Other36 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cetylpyridinium
Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.		7.1110pyridinium ion
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		3.3911C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0410acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
molybdenum disulfide
[no description available]		7.610sulfide salt
molybdenum
Molybdenum: A metallic element with the atomic symbol Mo, atomic number 42, and atomic weight 95.95. It is an essential trace element, being a component of the enzymes xanthine oxidase, aldehyde oxidase, and nitrate reductase.		7.610chromium group element atommicronutrient
octenidine
[no description available]		2.4110dihydropyridine
decamethoxine
decamethoxine: structure		2.6320quaternary ammonium salt
glycogen
glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.		210
calixarenes
Calixarenes: Phenolic metacyclophanes derived from condensation of PHENOLS and ALDEHYDES. The name derives from the vase-like molecular structures. A bracketed [n] indicates the number of aromatic rings.. calixarenes : Originally macrocyclic compounds capable of assuming a basket (or "calix") shaped conformation. They are formed from p-hydrocarbyl phenols and formaldehyde. The term now applies to a variety of derivatives by substitution of the hydrocarbon cyclo{oligo[(1,3-phenylene)methylene]}.. calixarene : A macrocycle composed of 1,3-phenylene groups linked by methylene groups. The number of 1,3-phenylene units in the macrocycle is denoted by the "n" in calix[n]arene name.		2.3110
sodium dodecyl sulfate
Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.		1.9710organic sodium saltdetergent;
protein denaturant
alpha-chymotrypsin
Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.		2.0410
alprostadil
[no description available]		3.3911prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
bacteriochlorophylls
Bacteriochlorophylls: Pyrrole containing pigments found in photosynthetic bacteria.		2.4110
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		2.7620biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
thimerosal
Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.		2.0610alkylmercury compoundantifungal drug;
antiseptic drug;
disinfectant;
drug allergen
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Conjunctivitides
[description not available]		02.0810
Conjunctivitis, Bacterial
Purulent infections of the conjunctiva by several species of gram-negative, gram-positive, or acid-fast organisms. Some of the more commonly found genera causing conjunctival infections are Haemophilus, Streptococcus, Neisseria, and Chlamydia.		02.0810
HIV Coinfection
[description not available]		0310
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		0310
Diabetic Feet
[description not available]		03.8321
Complications of Diabetes Mellitus
[description not available]		02.110
Ache
[description not available]		02.110
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.110
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.110
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		08.8321
Infection, Wound
[description not available]		02.4320
Chronic Illness
[description not available]		02.9340
Diseases of Nasopharynx
[description not available]		02.0410
Infection
[description not available]		02.0410
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.9340
Hypertrophy
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).		02.0410
Infections
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.		02.0410
Laryngitis
Inflammation of the LARYNGEAL MUCOSA, including the VOCAL CORDS. Laryngitis is characterized by irritation, edema, and reduced pliability of the mucosa leading to VOICE DISORDERS such as APHONIA and HOARSENESS.		02.0410
Tonsillitis
Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.		02.4420
Bacterial Disease
[description not available]		02.0210
Bacterial Infections
Infections by bacteria, general or unspecified.		02.0210
Phlegmon
[description not available]		07.0310
Jaw Diseases
Diseases involving the JAW.		02.0310
Cellulitis
An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.		02.0310
Pus
[description not available]		02.6930
Ischemia
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.		01.9910
Abscess, Pulmonary
[description not available]		01.9910
Empyema, Thoracic
[description not available]		01.9910
Bronchiectasis
Persistent abnormal dilatation of the bronchi.		01.9910
Lung Abscess
Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.		01.9910
Empyema, Pleural
Suppurative inflammation of the pleural space.		01.9910
Infection, Postoperative Wound
[description not available]		02.420
Abscess, Abdominal
[description not available]		0210
Abdominal Abscess
An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)		0210
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		03.3911
Acute Bacterial Prostatitis
[description not available]		01.9710
Prostatitis
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.		06.9710
Urethritis
Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both.		01.9710